Form 8-K Intra-Cellular Therapies For: Aug 12
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Intra-cellular Therapies, Inc. (ITCI) Tops Q2 EPS by 8c
August 12, 2014 7:46 AM EDTIntra-cellular Therapies, Inc. (NASDAQ: ITCI) reported Q2 EPS of ($0.15), $0.08 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $319.2 thousand versus the consensus estimate of $410 thousand.
For earnings history and earnings-related data on Intra-cellular Therapies, Inc. (ITCI) click here.
... More